Peripheral Artery Disease

Black and Hispanic patients with peripheral artery disease experience worse limb outcomes compared with white patients, even when presenting at a similar stage of clinical severity, data show.

New analyses from the REDUCE-IT study show icosapent ethyl significantly reduced total primary CV endpoints by 32% in patients with prior peripheral artery disease, suggesting substantial benefit for a high-risk population.

Peripheral artery disease and its most advanced form, critical limb ischemia, are major sources of morbidity and mortality, yet many patients are not diagnosed in time to prevent amputation.

In the interim results of the observational DISRUPT PAD III study, intravascular lithotripsy was safe and effective in patients with peripheral artery disease and calcified lesions, researchers reported at VIVA 21.

In patients with peripheral artery disease and femoropopliteal lesions, a low-dose paclitaxel-coated balloon enhanced patency and reduced risk for reintervention compared with percutaneous transluminal angioplasty, researchers reported.

In patients with complex peripheral artery disease, a drug-coated balloon performed similarly to how it did in the general PAD population, according to new data from the IN.PACT Global registry.

A drug-eluting stent outperformed bare-metal stents for treatment of patients with lesions in the superficial femoral and proximal popliteal arteries, according to results of the EMINENT trial presented at VIVA 21.

September is Peripheral Artery Disease awareness month; therefore, Healio and Cardiology Today have compiled a list of recent updates in PAD research and treatment.

Janssen Pharmaceuticals announced that the FDA has granted an expanded indication to rivaroxaban, now allowing it for use in patients who had recent lower-extremity revascularization due to symptomatic peripheral artery disease.

Royal Philips announced the FDA has granted breakthrough device designation for its laser-assisted inferior vena cava filter removal device.